DNA Repair Drugs: Global Markets
Report Scope:
This report provides an in-depth examination of the healthcare industry, with a particular emphasis on global market trend analysis. The report's goal is to provide an overview of the market for DNA repair drugs, as well as market segmentation by type, application and geography. During the forecast period, the market for DNA repair drugs is expected to grow rapidly. The report provides key statistics on the market status of the leading players in the DNA repair drug market, as well as key market trends and opportunities.
Report Includes:
- 20 data tables and 20 additional tables
- A brief general outlook of the global markets for DNA repair drugs within the biotech industry
- Analyses of the global market trends, with data from 2020 to 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Discussion of major factors driving the growth of global DNA repair drugs market, industry structure, regulatory scenario and penetration of technologies within the marketplace
- Highlights of key market dynamics (DROs), current trends and emerging applications, federal regulations and opportunity assessment of next generation technologies anticipated to drive the progress of this market
- Evaluation of current market size and revenue forecast for DNA repair drugs in dollar value terms, and corresponding market share analysis by technology type, application and region
- Assessment of new developments relate to DNA research and type classification, their improvement techniques, focused scene investigation and patterns of advancements
- Insight into the R&D spendings in the pharmaceutical industry, approval of new drugs, projected revenues and cost analyses
- Emphasis on the SARS-CoV-2 Infection Impairs on DNA repair and inhibits
- Profile descriptions of the leading market players, including AbbVie, Bayer AG, Eli Lilly and Co., Johnson & Johnson, Novartis and Sanofi
Companies Mentioned
ABBOTT LABORATORIES
ABBVIE INC.
AMGEN INC.
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB CO.
ELI LILLY
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO., INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
SANOFI S.A.
- Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Market Estimates
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Market and Technology Background
- DNA Damage
- Sources of DNA Damage
- DNA Repair Mechanism
- Base Excision Repair and Nucleotide Excision Repair
- Repair of Double-Strand Breaks
- Nucleotide Excision Repair
- Mismatch Repair
- Homologous Recombination (HR)
- Non-Homologous End Joining (NHEJ)
- Alternative End Joining
- Targets for Cancer Therapy
- DNA Damage Response for Cancer Chemotherapy
- Targeting PARP-1
- Targeting APE 1
- Targeting XRCC 1
- Targeting DNA-PKcs
- Targeting Ligases
- Targeting PI-3 kinase
- Chapter 4 Market Breakdown by Technology Type
- Poly(ADP-Ribose) Polymerase Inhibitors
- Structure and Function of PARP Inhibitors
- Use of PARP Inhibitors in Treatment
- FDA-approved PARP Inhibitors for Use in Cancer Treatment
- PARP Inhibitors in Clinical Trials
- Chapter 5 Market Breakdown by Application
- Ovarian Cancer
- Epidemiology of Ovarian Cancer
- Risk Factors for Ovarian Cancer
- Breast Cancer
- Risk Factors for Breast Cancer
- Signs and Symptoms
- Treatment
- Challenges
- Global Impact
- Chapter 6 Market Breakdown by Region
- Market Overview and Discussion
- Rise of DNA Repair Cases by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Chapter 7 R&D in the Pharmaceutical Industry
- Healthcare Expenditures
- Continued Emphasis on R&D Activities
- Trends in the Pharmaceutical Industry
- Factors Influencing Spending for R&D
- Trends in R&D Spending and New Drug Development
- R&D Spending
- New Drug Development
- Approvals of New Drugs
- Trends in Recent Drug Spending by Therapeutic Class
- Types of New Drug Development
- Factors Influencing R&D Spending
- Projected Revenues
- Revenues as Funding for R&D
- New Drug Costs in R&D
- Chapter 8 DNA Repair Inhibitors on SARS-CoV-2
- Biological Structure of SARS-CoV-2
- Viral Infection Induces DNA Damage
- Federal Funding for the Development of COVID-19 Vaccines
- Chapter 9 Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ABBOTT LABORATORIES
- ASTRAZENECA PLC
- BAYER AG
- BRISTOL-MYERS SQUIBB CO.
- ELI LILLY
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- GLAXOSMITHKLINE PLC
- JOHNSON & JOHNSON
- MERCK & CO., INC.
- MERCK KGAA
- NOVARTIS AG
- PFIZER INC.
- SANOFI S.A.
- List of Tables
- Summary Table : Global Market for DNA Repair Drugs, by Type, Through 2026
- Table 1 : Global Market for DNA Repair Drugs, by Type, Through 2026
- Table 2 : FDA-Approved PARP Inhibitors
- Table 3 : Global Market for DNA Repair Drugs, by Application, Through 2026
- Table 4 : Global Market for DNA Repair Drugs, by Region, Through 2026
- Table 5 : North American Market for DNA Repair Drugs, by Country, Through 2026
- Table 6 : European Market for DNA Repair Drugs, by Country, Through 2026
- Table 7 : Asia-Pacific Market for DNA Repair Drugs, by Country, Through 2026
- Table 8 : Rest of the World Market for DNA Repair Drugs, Through 2026
- Table 9 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
- Table 10 : AbbVie: Oncology Pharmaceutical Products Portfolio
- Table 11 : AbbVie: Marketed Products
- Table 12 : AbbVie: Key Developments, 2021
- Table 13 : Allergan PLC: Marketed Products
- Table 14 : Amgen: Oncology Pharmaceutical Products Portfolio
- Table 15 : AstraZeneca: Oncology Pharmaceutical Products Portfolio
- Table 16 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
- Table 17 : Bayer AG: Marketed Products
- Table 18 : Bayer AG: Oncology Pharmaceutical Products Portfolio
- Table 19 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
- Table 20 : Bristol-Myers Squibb: Oncology Pharmaceutical Products Portfolio
- Table 21 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
- Table 22 : Eli Lilly and Co.: Marketed Products
- Table 23 : Eli Lilly and Co.: Oncology Pharmaceutical Products Portfolio
- Table 24 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
- Table 25 : Roche: Oncology Pharmaceutical Products Portfolio
- Table 26 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
- Table 27 : Johnson & Johnson: Oncology Pharmaceutical Products Portfolio
- Table 28 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
- Table 29 : Merck & Co., Inc.: Marketed Products
- Table 30 : Merck & Co., Inc.: Oncology Pharmaceutical Products Portfolio
- Table 31 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
- Table 32 : Merck KGaA: Marketed Products
- Table 33 : Novartis: Oncology Pharmaceutical Products Portfolio
- Table 34 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
- Table 35 : Pfizer Inc.: Oncology Pharmaceutical Products Portfolio
- Table 36 : Pfizer Inc.: Marketed Products
- Table 37 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
- Table 38 : Sanofi: Oncology Pharmaceutical Products Portfolio
- Table 39 : Sanofi: Oncology Pharmaceutical Revenue, 2018-2020
- List of Figures
- Summary Figure : Global Market for DNA Repair Drugs, by Type, 2020-2026
- Figure 1 : Pathway of Cellular DNA Damage and Repair
- Figure 2 : Chemical Structural of DNA Nucleotides
- Figure 3 : Direct Repair of Thymine Dimers
- Figure 4 : Repair of O6 - Methylguanine
- Figure 5 : Short-Patch and Long-Patch BER Pathways
- Figure 6 : Mechanism of NHEJ Repair of Double-Strand Breaks in DNA
- Figure 7 : Characteristics-Based Excision Repair, Nucleotide Excision Repair and Mismatch Repair
- Figure 8 : DNA Double Stand Base Repair Pathway
- Figure 9 : Environmental Gear Selection
- Figure 10 : Global Market for DNA Repair Drugs, by Type, 2020-2026
- Figure 11 : Structure Schematic of PARP Molecule
- Figure 12 : Interaction Between PARP and HR
- Figure 13 : Chemical Structure Formula of PARP Inhibitors
- Figure 14 : Global Market for DNA Repair Drugs, by Application, 2020-2026
- Figure 15 : Incidence, Mortality and Prevalence of Ovarian Cancer
- Figure 16 : Ovarian Cancer by Region and Gender
- Figure 17 : Incidence, Mortality and Prevalence of Breast Cancer
- Figure 18 : Breast Cancer, by Region and Gender
- Figure 19 : Global Market Shares for DNA Repair Drugs, by Region, 2020
- Figure 20 : North American Market Shares for DNA Repair Drugs, by Country, 2020
- Figure 21 : European Market Shares for DNA Repair Drugs, by Country, 2020
- Figure 22 : Asia-Pacific Market Shares for DNA Repair Drugs, by Country, 2020
- Figure 23 : R&D Intensities for Publicly Traded U.S. Companies
- Figure 24 : Annual Approvals of New Drugs by FDA
- Figure 25 : New Drug Approvals
- Figure 26 : U.S. Retail Drug Spending by Therapeutic Area
- Figure 27 : BARDA Funding for COVID-19 Vaccine
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook